NCT02595866 2024-08-09Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and CancerNational Cancer Institute (NCI)Phase 1 Completed58 enrolled 17 charts